Examination of the clinical meaning of the fever after zoledronic acid administration for therapy of bone metastasis arising from prostate cancer
Not Applicable
- Conditions
- Hormone therapy naive prostate cancer patient with bone metastasis
- Registration Number
- JPRN-UMIN000013290
- Lead Sponsor
- Chugoku Shikoku Genitourinary Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patient received hormoe therapy previously 2. Patient plans the radiation therapy to the prostate with hormone therapy 3. Patient administered NSAIDs or corticosteroid 4. Patient with a severe renal function disorder 5. Patient that is continuing dental treatment such as the tooth extraction 6. Patient with severe psychosis 7. Patient with double cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PSA normalization rate (less than 4ng/ml) as of three months after start of the treatment
- Secondary Outcome Measures
Name Time Method